EPIVIR
lamivudine
- Strength
- 300 mg/1
- Form
- Tablet, Film Coated
- Class
- Hepatitis B Virus Nucleoside Analog Rev…
ViiV Healthcare Company
Listed by Apotex Corp.
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 60505-3250 |
| FDA application | ANDA202941 |
| RxNorm concept | 205328 |
| Package sizes listed | 1 |
| Marketed since | January 2014 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
lamivudine
ViiV Healthcare Company
lamivudine
ViiV Healthcare Company
lamivudine
ViiV Healthcare Company
Major Pharmaceuticals
Ingenus Pharmaceuticals, LLC
Strides Pharma Science Limited
Coupler LLC
lamivudine oral
Chartwell RX, LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.